PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33325136-6 2021 Exosomes derived from CDDP-resistant cells were shown to reduce the sensitivity of MG63 and U2OS cells to CDDP, inhibit apoptosis, and increase the expression of multidrug resistance-associated protein 1 and P-glycoprotein. Cisplatin 22-26 ATP binding cassette subfamily C member 1 Homo sapiens 162-203 34053427-11 2022 (5) Significantly, the combination of Celastrol and DDP reduced the expression of P-gp, MRP1, and BCRP in the SGC7901/DPP cells. Cisplatin 52-55 ATP binding cassette subfamily C member 1 Homo sapiens 88-92 33570734-14 2021 Moreover, ABCC1 was a downstream target of miR-101, and miR-101 overexpression inhibited the progression of NSCLC cells and increased cisplatin sensitivity by targeting ABCC1. Cisplatin 134-143 ATP binding cassette subfamily C member 1 Homo sapiens 10-15 33570734-14 2021 Moreover, ABCC1 was a downstream target of miR-101, and miR-101 overexpression inhibited the progression of NSCLC cells and increased cisplatin sensitivity by targeting ABCC1. Cisplatin 134-143 ATP binding cassette subfamily C member 1 Homo sapiens 169-174 33123242-12 2020 The expression levels of drug efflux proteins, such as multidrug resistance-associated protein 1 and ATP-binding cassette sub-family G member 2, were significantly decreased when A549/DDP cells were treated with a combination of cisplatin and NVP-BEZ235 compared with the control group. Cisplatin 229-238 ATP binding cassette subfamily C member 1 Homo sapiens 55-96 33649818-0 2021 LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating MDR1 expression. Cisplatin 26-35 ATP binding cassette subfamily C member 1 Homo sapiens 82-86 33205540-7 2021 Moreover, intervention of WTAP evidently prohibited NKTCL cell chemotherapy resistance to cisplatin, as reflected by a lower inhibition of cell viability and decreased expression of drug resistance-associated protein expression MRP-1 and P-gp in YTS and SNK-6 cells. Cisplatin 90-99 ATP binding cassette subfamily C member 1 Homo sapiens 228-233 33029084-7 2020 A pan-MRP inhibitor, probenecid, can resecure cisplatin resistance leading by radiation. Cisplatin 46-55 ATP binding cassette subfamily C member 1 Homo sapiens 6-9 32536824-10 2020 SNHG16 silencing weakened cisplatin resistance, reflected by the reduction of IC50 value, down-regulation of MRP-1 and P-gp protein expression, suppression of proliferation, migration and invasion, as well as enhancement of apoptosis in SNHG16 deletion cisplatin-resistant neuroblastoma cells. Cisplatin 26-35 ATP binding cassette subfamily C member 1 Homo sapiens 109-114 32446175-0 2020 EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis. Cisplatin 48-57 ATP binding cassette subfamily C member 1 Homo sapiens 99-104 31986409-12 2020 In conclusion, the high-expression of circPVT1 is related with the cisplatin and pemetrexed insensitivity of LAD patients, circPVT1 contributes to cisplatin and pemetrexed chemotherapy resistance through miR-145-5p/ABCC1 axis. Cisplatin 67-76 ATP binding cassette subfamily C member 1 Homo sapiens 215-220 32523334-14 2020 Mechanistic investigations uncovered that the tumor-inhibiting effects of the co-treatment were mediated by repressing MDR, including MRP1 and P-Gp protein, thereby enhancing the efficiency of cisplatin. Cisplatin 193-202 ATP binding cassette subfamily C member 1 Homo sapiens 134-138 32523334-16 2020 Combination with leonurine may serve as a novel strategy for enhancing cisplatin sensitivity via the inhibition of the expression of MRP1 and P-Gp. Cisplatin 71-80 ATP binding cassette subfamily C member 1 Homo sapiens 133-137 31579410-8 2019 Additionally, multidrug-resistance-associated protein 1 and lung resistance protein expression was significantly higher in A549/DDP cells compared with that in A549 cells (P<0.05), with these levels increasing further in A549/DDP (P<0.05) but not A549 cells upon cisplatin treatment (P>0.05). Cisplatin 263-272 ATP binding cassette subfamily C member 1 Homo sapiens 14-55 31659146-4 2019 In H460/DDP and A549/DDP cells, expression of XIST, microRNA (miR)-144-3p, MDR1, and multidrug resistance-associated protein 1 (MRP1) were detected by quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot. Cisplatin 21-24 ATP binding cassette subfamily C member 1 Homo sapiens 128-132 31380278-9 2019 The cisplatin-treated H had higher transcription levels of ABCC1, DHRS2/HEP27, and EFEMP1 compared to cisplatin-treated-J cybrids. Cisplatin 4-13 ATP binding cassette subfamily C member 1 Homo sapiens 59-64 31659146-4 2019 In H460/DDP and A549/DDP cells, expression of XIST, microRNA (miR)-144-3p, MDR1, and multidrug resistance-associated protein 1 (MRP1) were detected by quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot. Cisplatin 8-11 ATP binding cassette subfamily C member 1 Homo sapiens 128-132 27906433-0 2016 MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Cisplatin 82-91 ATP binding cassette subfamily C member 1 Homo sapiens 106-111 31169018-10 2019 LW6-treated A549 cells showed an increase in ROS level that blocked the hypoxia induced resistance to cisplatin and in addition, decreased expression of MDR1 and MRP1 in cisplatin-treated cells. Cisplatin 170-179 ATP binding cassette subfamily C member 1 Homo sapiens 162-166 31169018-11 2019 This study revealed that hypoxia-improved cisplatin chemoresistance of NSCLC cells by regulated MDR1 and MRP1 expression via HIF1alpha/ROS pathway is reversed by LW6, suggesting that LW6 may act as effective sensitizer in chemotherapy for NSCLC. Cisplatin 42-51 ATP binding cassette subfamily C member 1 Homo sapiens 105-109 29548748-8 2018 Additionally, MALAT1 knockdown inhibited the Notch1 pathway and ABCC1 expression in CDDP-resistant ovarian cancer cells. Cisplatin 84-88 ATP binding cassette subfamily C member 1 Homo sapiens 64-69 29299132-7 2017 Colchicine was used as the substrate for P-glycoprotein (Pgp) and multidrug resistance protein (MRP) 1, cisplatin was used as the substrate for Mrp2 and organic cation transporters 2 (Oct2), and verapamil and MK571 were used as inhibitors of Pgp and MRP1, respectively. Cisplatin 104-113 ATP binding cassette subfamily C member 1 Homo sapiens 66-102 29299132-7 2017 Colchicine was used as the substrate for P-glycoprotein (Pgp) and multidrug resistance protein (MRP) 1, cisplatin was used as the substrate for Mrp2 and organic cation transporters 2 (Oct2), and verapamil and MK571 were used as inhibitors of Pgp and MRP1, respectively. Cisplatin 104-113 ATP binding cassette subfamily C member 1 Homo sapiens 250-254 28443990-12 2017 Moreover, induced expression of LPAATbeta compromised the effects of miR-340-5p on CDDP-induced cell death and accumulation of MRP1 and MDR1. Cisplatin 83-87 ATP binding cassette subfamily C member 1 Homo sapiens 127-131 28075474-5 2017 We demonstrated that CLS-354/DX cells overexpressing multidrug resistance-associated protein 1 (MRP1) were resistant to anticancer drugs cisplatin and camptothecin. Cisplatin 137-146 ATP binding cassette subfamily C member 1 Homo sapiens 53-94 28075474-5 2017 We demonstrated that CLS-354/DX cells overexpressing multidrug resistance-associated protein 1 (MRP1) were resistant to anticancer drugs cisplatin and camptothecin. Cisplatin 137-146 ATP binding cassette subfamily C member 1 Homo sapiens 96-100 31173289-2 2019 PATIENTS AND METHODS: We detected the expressions of SNHG5, apoptosis-specific genes (Bax and Bcl-2) and drug resistance-specific genes (MDR1 and MRP1) in cisplatin-sensitive and cisplatin-resistant GC patients. Cisplatin 155-164 ATP binding cassette subfamily C member 1 Homo sapiens 146-150 27906433-14 2016 CONCLUSIONS: The results of the present study demonstrated that inhibition of miR-185-5p was involved in chemo-resistance of NSCLC cells to cisplatin via down-regulating ABCC1. Cisplatin 140-149 ATP binding cassette subfamily C member 1 Homo sapiens 170-175 26852750-0 2016 miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Cisplatin 41-50 ATP binding cassette subfamily C member 1 Homo sapiens 65-106 27485374-9 2016 It blocked the chemoresistance of T24 and J82 cells to cisplatin through suppressing the expression of MRP1. Cisplatin 55-64 ATP binding cassette subfamily C member 1 Homo sapiens 103-107 27485374-11 2016 Consistent with in vitro experiments, emodin/cisplatin co-treatment increased the cell apoptosis and repressed the MRP1 expression in xenograft tumors, and without obvious systemic toxicity. Cisplatin 45-54 ATP binding cassette subfamily C member 1 Homo sapiens 115-119 27485374-12 2016 CONCLUSIONS: This study revealed that emodin could increase the cisplatin-induced cytotoxicity against T24 and J82 cells via elevating the cellular ROS level and downregulating MRP1 expression. Cisplatin 64-73 ATP binding cassette subfamily C member 1 Homo sapiens 177-181 26852750-7 2016 Further, we found that miR-145 accelerated MRP1 mRNA degradation by directly targeting its 3"-UTR and therefore caused increased cisplatin toxicity in GBC cells. Cisplatin 129-138 ATP binding cassette subfamily C member 1 Homo sapiens 43-47 21903448-3 2011 We demonstrated that down-regulation of MRP1 in MC3/5FU, a drug-resistant MEC cell line, by RNA interference increased the drug sensitivity of the cells to 5-fluorouracil, doxorubicin, pharmorubicin, bleomycin-A5, cis-platinum and taxol. Cisplatin 214-226 ATP binding cassette subfamily C member 1 Homo sapiens 40-44 27284014-4 2016 We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin. Cisplatin 179-188 ATP binding cassette subfamily C member 1 Homo sapiens 76-81 26721606-6 2016 The possible mechanisms responsible for the enhanced cytotoxicity of proadifen/CDDP combined treatment may be attributed to a decrease of reduced relative glutathione levels, downregulation of multidrug resistance-associated proteins 1 and 2 (MRP1, MRP2) and attenuation of survivin expression. Cisplatin 79-83 ATP binding cassette subfamily C member 1 Homo sapiens 193-241 26721606-6 2016 The possible mechanisms responsible for the enhanced cytotoxicity of proadifen/CDDP combined treatment may be attributed to a decrease of reduced relative glutathione levels, downregulation of multidrug resistance-associated proteins 1 and 2 (MRP1, MRP2) and attenuation of survivin expression. Cisplatin 79-83 ATP binding cassette subfamily C member 1 Homo sapiens 243-247 24103265-7 2013 Compared with the control group, IC50; of shMRE11 group treated with DDP, MMC, ADM, 5-FU was reduced significantly as shown by MTT assay (P<0.05); qRT-PCR and Western blot analysis of MRP1 showed that its expression significantly decreased at the mRNA and protein levels (P<0.05). Cisplatin 69-72 ATP binding cassette subfamily C member 1 Homo sapiens 187-191 22941407-0 2012 Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1. Cisplatin 37-46 ATP binding cassette subfamily C member 1 Homo sapiens 124-165 27485374-0 2016 Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. Cisplatin 16-25 ATP binding cassette subfamily C member 1 Homo sapiens 103-107 25580427-0 2014 Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation. Cisplatin 16-25 ATP binding cassette subfamily C member 1 Homo sapiens 100-104 21793937-10 2012 Finally, Western blot showed that higher expressions of MRP1, LRP, and BCL2 and lower expression of TopoIIbeta were observed in SCC-15/cisplatin cells than in clinical samples. Cisplatin 135-144 ATP binding cassette subfamily C member 1 Homo sapiens 56-60 20005867-8 2010 In addition, the overexpression of fully glycosylated MRP1 or MRP4 in tumor cell line of ovarian origin was associated with resistance to oxaliplatin and cisplatin. Cisplatin 154-163 ATP binding cassette subfamily C member 1 Homo sapiens 54-58 20458768-10 2010 CONCLUSION: Multiple drug resistance of multiple drugs in the human hepatoma cell line SK-Hep-1/CDDP was closely related to the overexpression of MDR1 and MRP1. Cisplatin 96-100 ATP binding cassette subfamily C member 1 Homo sapiens 155-159 20459793-8 2010 For kaempferol, which shows a significant synergistic interaction with cisplatin, expression of ABCC1, ABCC5, ABCC6, NFkB1, cMyc, and CDKN1A genes was further examined. Cisplatin 71-80 ATP binding cassette subfamily C member 1 Homo sapiens 96-101 15517878-8 2004 In conclusion, COX-2 overexpression induced increased MRP-1 expression in a colon cancer cell line, TR-5, resulting in chemoresistance to CDDP that was approximately triple the level of chemoresistance observed in the original HCT-15 cells line, as measured by calculation of the IC50. Cisplatin 138-142 ATP binding cassette subfamily C member 1 Homo sapiens 54-59 18695918-8 2008 These results suggested that the overexpression of COX-2 increases the intracellular production of MRP1 and MRP2 and causes drug resistance to CDDP. Cisplatin 143-147 ATP binding cassette subfamily C member 1 Homo sapiens 99-103 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 121-125 ATP binding cassette subfamily C member 1 Homo sapiens 37-42 14671431-6 2003 Lonafarnib is shown here to inhibit the function of MRP1 and MRP2 with a potency similar to that of cyclosporin A and may therefore cause the observed synergy with cisplatin and other agents by inhibiting these MRPs. Cisplatin 164-173 ATP binding cassette subfamily C member 1 Homo sapiens 52-56 16107775-4 2004 The chemosensitivity against 5-FU, SN-38, MMC and CDDP was independent of MDR1 C3435T, MRP1 G2168A, and MRP2 C-24T (C3972T), possibly due to no association with the growth rate of and mRNA expression levels of MDR1, MRP1 and MRP2 in the adenocarcinoma, however, MDR1 C3435T tended to be accompanied with a higher expression of MDR1 mRNA. Cisplatin 50-54 ATP binding cassette subfamily C member 1 Homo sapiens 216-220 12079522-12 2002 Except for HAC-2 cells, expression of MRP genes was related to CDDP resistance, and MDR-1 gene expression was associated with PTX resistance. Cisplatin 63-67 ATP binding cassette subfamily C member 1 Homo sapiens 38-41 11259628-7 2001 On the other hand, inhibition of GST and GS-X pump by ethacrynic acid, quercetin, tannic acid, and indomethacin at concentrations that inhibited activities of GST and GS-X pump by more than 50% had no significant effects on cisplatin cytotoxicity and cisplatin-induced DNA ICL in these cells. Cisplatin 224-233 ATP binding cassette subfamily C member 1 Homo sapiens 41-45 11500053-5 2001 The cisplatin-resistant HCT-8 cells (HCT-8DDP cells) overexpressed MRP and MDR1 genes, and showed resistance to not only cisplatin (CDDP), but also doxorubicin (DOX) and etoposide (VP-16). Cisplatin 4-13 ATP binding cassette subfamily C member 1 Homo sapiens 67-70 11259628-7 2001 On the other hand, inhibition of GST and GS-X pump by ethacrynic acid, quercetin, tannic acid, and indomethacin at concentrations that inhibited activities of GST and GS-X pump by more than 50% had no significant effects on cisplatin cytotoxicity and cisplatin-induced DNA ICL in these cells. Cisplatin 224-233 ATP binding cassette subfamily C member 1 Homo sapiens 167-171 11259628-7 2001 On the other hand, inhibition of GST and GS-X pump by ethacrynic acid, quercetin, tannic acid, and indomethacin at concentrations that inhibited activities of GST and GS-X pump by more than 50% had no significant effects on cisplatin cytotoxicity and cisplatin-induced DNA ICL in these cells. Cisplatin 251-260 ATP binding cassette subfamily C member 1 Homo sapiens 41-45 11259628-7 2001 On the other hand, inhibition of GST and GS-X pump by ethacrynic acid, quercetin, tannic acid, and indomethacin at concentrations that inhibited activities of GST and GS-X pump by more than 50% had no significant effects on cisplatin cytotoxicity and cisplatin-induced DNA ICL in these cells. Cisplatin 251-260 ATP binding cassette subfamily C member 1 Homo sapiens 167-171 10944550-6 2000 MRP1 can even confer resistance to arsenite and MRP2 to cisplatin, again probably by transporting these compounds in complexes with GSH. Cisplatin 56-65 ATP binding cassette subfamily C member 1 Homo sapiens 0-4 11259628-1 2001 Glutathione (GSH), glutathione S-transferase (GST), and glutathione conjugate export pump (GS-X pump) have been shown to participate collectively in the detoxification of many anticancer drugs, including cisplatin. Cisplatin 204-213 ATP binding cassette subfamily C member 1 Homo sapiens 91-95 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 193-202 ATP binding cassette subfamily C member 1 Homo sapiens 52-56 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 193-202 ATP binding cassette subfamily C member 1 Homo sapiens 52-55 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 318-327 ATP binding cassette subfamily C member 1 Homo sapiens 52-56 10699972-6 2000 Immunoblotting with specific antibodies directed to MRP1 and MRP2 (cMOAT) also showed that expression of these two ABC transporter genes was considerably reduced in 7404-CP20 cells and another cisplatin-resistant cell line KB-CP20, in contradistinction to previous studies suggesting that MRP might be responsible for cisplatin efflux. Cisplatin 318-327 ATP binding cassette subfamily C member 1 Homo sapiens 52-55 10433011-2 1999 The signals of the MDR1, MRP, topoisomerase IIalpha, and topoisomerase IIbeta genes in HepG2 were weakened when IFN-alpha was added to CDDP. Cisplatin 135-139 ATP binding cassette subfamily C member 1 Homo sapiens 25-28 10427140-3 1999 The human gene for cMOAT (<canalicular multispecific organic anion transporter>), a homologue of MRP, is thought to mediate hepatobiliary excretion of organic anions and to be associated with cisplatin resistance. Cisplatin 198-207 ATP binding cassette subfamily C member 1 Homo sapiens 103-106 10100721-7 1999 In addition, the mRNA levels of both MRP and MRP3 correlated with resistance of the cell lines to vincristine, VP-16, and cis-diamminedichloroplatinum(II). Cisplatin 122-150 ATP binding cassette subfamily C member 1 Homo sapiens 37-40 10363583-0 1999 Differences in substrate specificity among glutathione conjugates (GS-X) pump family members: comparison between multidrug resistance-associated protein and a novel transporter expressed on a cisplatin-resistant cell line (KCP-4). Cisplatin 192-201 ATP binding cassette subfamily C member 1 Homo sapiens 67-71 9776312-0 1998 Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Cisplatin 213-222 ATP binding cassette subfamily C member 1 Homo sapiens 23-51 9776312-0 1998 Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Cisplatin 213-222 ATP binding cassette subfamily C member 1 Homo sapiens 53-56 19002785-11 1998 The expression of MRP1 and gamma-GCS genes can be coordinately up-regulated by cisplatin, 1-[5-(4-amino-2-methyl)pyrimidyl]methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), and heavy metals in human cancer cells. Cisplatin 79-88 ATP binding cassette subfamily C member 1 Homo sapiens 18-22 9515571-3 1998 We have shown recently that the MRP and gamma-glutamylcysteine synthetase (gamma-GCS) heavy subunit mRNA levels are coordinately overexpressed in cisplatin (CP)-resistant human leukemia cells (Ishikawa et al., J Biol Chem 271: 14981-14988, 1996) and frequently co-elevated in human colorectal tumors (Kuo et al., Cancer Res 56: 3642-3644, 1996). Cisplatin 146-155 ATP binding cassette subfamily C member 1 Homo sapiens 32-35 9683290-1 1998 The level of expression of the multidrug resistance-associated protein (MRP1) in a panel of human ovarian carcinoma cell lines and their variants with acquired cisplatin resistance was determined using Western blotting. Cisplatin 160-169 ATP binding cassette subfamily C member 1 Homo sapiens 31-76 9683290-3 1998 In addition, we have transfected the MRP1 gene into an intrinsically cisplatin-resistant cell line SKOV3, previously shown to have elevated levels of glutathione (GSH). Cisplatin 69-78 ATP binding cassette subfamily C member 1 Homo sapiens 37-41 9683290-4 1998 The MRP1-transfected line SKOV3-S2 was shown to be cross-resistant to doxorubicin, vincristine and etoposide but not to paclitaxel, vinblastine and platinum agents, such as cisplatin, JM216 [bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV)] and AMD473 [cis-ammine dichloro (2-methyl-pyridine) platinum (II)]. Cisplatin 173-182 ATP binding cassette subfamily C member 1 Homo sapiens 4-8 9119737-5 1997 These data suggest that the GS-X pump itself influences cisplatin resistance, as well as cellular GSH content. Cisplatin 56-65 ATP binding cassette subfamily C member 1 Homo sapiens 28-32 9063478-2 1997 It is suggested that GS-X pump expression is related to cellular GSH metabolism and involved in cisplatin resistance. Cisplatin 96-105 ATP binding cassette subfamily C member 1 Homo sapiens 21-25 9155157-2 1997 The GS-X pump was suggested to be involved in reducing the accumulation of cisplatin in KCP-4 cells. Cisplatin 75-84 ATP binding cassette subfamily C member 1 Homo sapiens 4-8 8663001-10 1996 These observations suggest that elevated expression of the MRP/GS-X pump and increased GSH biosynthesis together may be important factors in the cellular metabolism and disposition of cisplatin, alkylating agents, and heavy metals. Cisplatin 184-193 ATP binding cassette subfamily C member 1 Homo sapiens 63-67 8862010-1 1996 We provide evidence that the expression of the human MRP/GS-X pump encoded by the MRP (multidrug resistance associated protein) gene is induced by cisplatin in human leukemia HL-60/R-CP (cisplatin-resistant) cells and modulates cell growth inhibition by delta(7)-prostaglandin A1 (PGA1) methyl ester. Cisplatin 147-156 ATP binding cassette subfamily C member 1 Homo sapiens 57-61 8663001-1 1996 We recently reported that GS-X pump activity, as assessed by ATP-dependent transport of the glutathione-platinum complex and leukotriene C4, and intracellular glutathione (GSH) levels were remarkably enhanced in cis-diamminedichloroplatinum(II) (cisplatin)-resistant human leukemia HL-60 cells (Ishikawa, T., Wright, C. D., and Ishizuka, H. (1994) J. Biol. Cisplatin 212-240 ATP binding cassette subfamily C member 1 Homo sapiens 26-30 8663001-1 1996 We recently reported that GS-X pump activity, as assessed by ATP-dependent transport of the glutathione-platinum complex and leukotriene C4, and intracellular glutathione (GSH) levels were remarkably enhanced in cis-diamminedichloroplatinum(II) (cisplatin)-resistant human leukemia HL-60 cells (Ishikawa, T., Wright, C. D., and Ishizuka, H. (1994) J. Biol. Cisplatin 246-255 ATP binding cassette subfamily C member 1 Homo sapiens 26-30 8663001-4 1996 Now, using Northern hybridization and RNase protection assay, we provide evidence that the multidrug resistance-associated protein (MRP) gene, which encodes a human GS-X pump, is expressed at higher levels in cisplatin-resistant (HL-60/R-CP) cells than in sensitive cells, whereas amplification of the MRP gene is not detected by Southern hybridization. Cisplatin 209-218 ATP binding cassette subfamily C member 1 Homo sapiens 165-169 8862010-1 1996 We provide evidence that the expression of the human MRP/GS-X pump encoded by the MRP (multidrug resistance associated protein) gene is induced by cisplatin in human leukemia HL-60/R-CP (cisplatin-resistant) cells and modulates cell growth inhibition by delta(7)-prostaglandin A1 (PGA1) methyl ester. Cisplatin 187-196 ATP binding cassette subfamily C member 1 Homo sapiens 57-61 8862010-3 1996 In cisplatin-sensitive HL-60 cells, which express the MRP/GS-X pump at low levels, c-myc expression was substantially suppressed by delta(7)-PGA1 methyl ester and the cell cycle was arrested in G1 phase. Cisplatin 3-12 ATP binding cassette subfamily C member 1 Homo sapiens 58-62 7966417-3 1994 A previous study has suggested that the adenosine triphosphate (ATP)-dependent glutathione S-conjugate export pump (GS-X pump), which exports the bis-(glutathionato)-platinum (II) (GS-platinum) complex, could contribute to cellular resistance to cisplatin. Cisplatin 246-255 ATP binding cassette subfamily C member 1 Homo sapiens 116-120 7488097-1 1995 The ATP-dependent glutathione S-conjugate export pump (GS-X pump) has been suggested to play a role in the mechanism of cisplatin resistance. Cisplatin 120-129 ATP binding cassette subfamily C member 1 Homo sapiens 55-59 7488097-2 1995 The purpose of this study was to determine the relationship between intracellular glutathione (GSH) levels and GS-X pump activity and whether GS-X pump overexpression results in cisplatin resistance. Cisplatin 178-187 ATP binding cassette subfamily C member 1 Homo sapiens 142-146 7488097-7 1995 In conclusion, GS-X pump expression is related to cellular GSH metabolism and involved in cisplatin resistance. Cisplatin 90-99 ATP binding cassette subfamily C member 1 Homo sapiens 15-19 7961875-0 1994 GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. Cisplatin 43-76 ATP binding cassette subfamily C member 1 Homo sapiens 0-4 7961875-1 1994 The ATP-dependent glutathione S-conjugate export pump, named GS-X pump, has been shown to eliminate a potentially cytotoxic glutathione-platinum (GS.Pt) complex from tumor cells, thereby modulating glutathione (GSH)-associated resistance to cis-diamminedichloroplatinum(II) (cisplatin) (Ishikawa, T., and Ali-Osman, F. (1993) J. Biol. Cisplatin 241-269 ATP binding cassette subfamily C member 1 Homo sapiens 61-65 7961875-1 1994 The ATP-dependent glutathione S-conjugate export pump, named GS-X pump, has been shown to eliminate a potentially cytotoxic glutathione-platinum (GS.Pt) complex from tumor cells, thereby modulating glutathione (GSH)-associated resistance to cis-diamminedichloroplatinum(II) (cisplatin) (Ishikawa, T., and Ali-Osman, F. (1993) J. Biol. Cisplatin 275-284 ATP binding cassette subfamily C member 1 Homo sapiens 61-65 7961875-4 1994 The present study provides evidence that the GS-X pump is functionally overexpressed in cisplatin-resistant human promyelocytic leukemia HL-60 (HL-60/R-CP) cells, in which the cellular GSH level was substantially enhanced. Cisplatin 88-97 ATP binding cassette subfamily C member 1 Homo sapiens 45-49 7961875-12 1994 These results suggest that the expression of the GS-X pump in both cisplatin-resistant and -sensitive cells is related to cell proliferation. Cisplatin 67-76 ATP binding cassette subfamily C member 1 Homo sapiens 49-53 7966417-4 1994 PURPOSE: In this study, we examined whether the active efflux pump for cisplatin in the cisplatin-resistant KB cells is the GS-X pump and tested its activity by using an endogenous substrate, [3H]leukotriene C4 ([3H]LTC4). Cisplatin 71-80 ATP binding cassette subfamily C member 1 Homo sapiens 124-128 7966417-4 1994 PURPOSE: In this study, we examined whether the active efflux pump for cisplatin in the cisplatin-resistant KB cells is the GS-X pump and tested its activity by using an endogenous substrate, [3H]leukotriene C4 ([3H]LTC4). Cisplatin 88-97 ATP binding cassette subfamily C member 1 Homo sapiens 124-128 7966417-12 1994 IMPLICATIONS: Our study suggests that the GS-X pump is involved in the decreased accumulation of cisplatin in KCP-4 cells. Cisplatin 97-106 ATP binding cassette subfamily C member 1 Homo sapiens 42-46 34747666-10 2021 Furthermore, tube formation by human umbilical vein endothelial cells, TNF-alpha and VEGF secretion, and the levels of MRP1, ABCG1, ABCA1, and NLRP3 expression in cisplatin-resistant Eca-109 and TE1 cells were all reduced by miR-495 mimics. Cisplatin 163-172 ATP binding cassette subfamily C member 1 Homo sapiens 119-123 34522245-11 2021 After cisplatin treatment, down-regulation of BANCR could consequently attenuate TU686-DDP-R and TU177-DDP-R cell proliferation, and the expression of MRP1, Bcl-2, and p-PKB was decreased and Bax was increased. Cisplatin 6-15 ATP binding cassette subfamily C member 1 Homo sapiens 151-155 34523261-0 2021 Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis. Cisplatin 95-104 ATP binding cassette subfamily C member 1 Homo sapiens 119-124 34339285-0 2021 Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating ABCC1 Through miR-186-5p. Cisplatin 34-43 ATP binding cassette subfamily C member 1 Homo sapiens 111-116 35205642-0 2022 Activation of ABCC Genes by Cisplatin Depends on the CoREST Occurrence at Their Promoters in A549 and MDA-MB-231 Cell Lines. Cisplatin 28-37 ATP binding cassette subfamily C member 1 Homo sapiens 14-18 35205642-3 2022 To test the possible molecular basis of increased expression of ABCC subfamily members in a cisplatin therapy mimicking model, we generated two cisplatin-resistant cell lines derived from non-small cell lung cancer cells (A549) and triple-negative breast cancer cells (MDA-MB-231). Cisplatin 92-101 ATP binding cassette subfamily C member 1 Homo sapiens 64-68 35205642-3 2022 To test the possible molecular basis of increased expression of ABCC subfamily members in a cisplatin therapy mimicking model, we generated two cisplatin-resistant cell lines derived from non-small cell lung cancer cells (A549) and triple-negative breast cancer cells (MDA-MB-231). Cisplatin 144-153 ATP binding cassette subfamily C member 1 Homo sapiens 64-68 35205642-4 2022 Analysis of data for A549 cells deposited in UCSC Genome Browser provided evidence on the negative interdependence between the occurrence of the CoREST complex at the gene promoters and the overexpression of ABCC genes in cisplatin-resistant lung cancer cells. Cisplatin 222-231 ATP binding cassette subfamily C member 1 Homo sapiens 208-212 35205642-8 2022 In summary, the CoREST complex prevents the overexpression of some multidrug resistance proteins from the ABCC subfamily in cancer cells exposed to cisplatin. Cisplatin 148-157 ATP binding cassette subfamily C member 1 Homo sapiens 106-110